srd-001
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2021 (NCT04703842)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Sarcoplasmic/endoplasmic reticulum calcium ATPase 2Supplementation
ATP2A2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06224660 | Phase 1 | Mar 31, 2024 | Sardocor Corp. |
| NCT04703842 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2021 | Covance, Sardocor Corp. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sardocor Corp. | For profit | 2 | 2 | 2 | 2021 |
| Covance | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1